These advances have made targeted therapies the preferred first-line treatment in ALK- and EGFR-positive NSCLC with brain metastases, establishing a paradigm shift toward systemic CNS-directed therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.